COMMUNIQUÉS West-GlobeNewswire

Ashvattha Therapeutics Appoints Ophthalmology Veteran Robert J. Dempsey as Interim CEO Following Positive Phase 2 Results and FDA Alignment on Pivotal Program
14/10/2025
FDA agrees with Phase 2b/3 clinical design, including primary endpoint and development approach, providing clear regulatory pathway to conduct two studies under single protocol Dempsey brings proven track record of [...]
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
14/10/2025
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the [...]
Halda Therapeutics Announces Oral Plenary Presentation on HLD-0915 Clinical Data in Metastatic Castration-Resistant Prostate Cancer (mCRPC) at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics on October 24, 2025
14/10/2025
Plenary Presentation to be Followed by Poster Presentation Highlighting HLD-0915 Clinical Data BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company [...]
Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit
14/10/2025
– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE [...]
Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025
14/10/2025
Telitacicept met primary and all secondary endpoints, demonstrating clinically meaningful improvements in disease activity versus placebo ~71.8% of patients receiving telitacicept 160mg achieved ≥3-point ESSDAI (EULAR [...]
Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
14/10/2025
Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus [...]
Predictive Oncology Announces Additions to Board and Leadership Team to Support Digital Asset Treasury Strategy
14/10/2025
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, [...]
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
14/10/2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, in collaboration with its Canadian [...]
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
14/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the [...]
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
14/10/2025
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , ( [...]
R1 to Acquire Phare Health, a Leading AI Platform for Automating Inpatient Coding and Pre-Bill Clinical Documentation Improvement
14/10/2025
Acquisition Expands R1’s Agentic AI Capabilities to Help Providers Unlock Clinical and Financial Value MURRAY, Utah, Oct. 14, 2025 (GLOBE NEWSWIRE) -- R1 (“R1” or the “Company”), an industry leader in managing and [...]
SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months
14/10/2025
42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best [...]
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
14/10/2025
EMERYVILLE, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
14/10/2025
NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
14/10/2025
$50 million drawn down at closing, with access to up to an additional $80 million Strengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC) [...]
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides
14/10/2025
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to [...]
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
14/10/2025
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established [...]
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
14/10/2025
CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
FibroBiologics to Present at the 2025 ThinkEquity Conference
14/10/2025
HOUSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]

Pages